加替沙星序贯治疗急性泌尿系统感染的经济学评价

Pharmacoeconomic Evaluation of Sequential Therapy of Gatifloxacin for Acute Urinary System Infections

目的:评价加替沙星序贯治疗急性泌尿系统感染的经济学效果。方法:76例急性泌尿系统感染患者随机分为对照组(37例)、序贯组(39例),对照组给予加替沙星注射液200mg静脉滴注,bid,连用8d;序贯组先用加替沙星注射液200mg静脉滴注,bid,连用4d后改为口服加替沙星片200mg,bid,连用4d,观察疗效,并进行最小成本分析。结果:对照组与序贯组有效率分别为97.3%和94.9%,不良反应发生率分别为5.4%和5.1%,细菌清除率分别为87.8%和86.5%,2组差异均无统计学意义(P>0.05)。但对照组总成本为502.40元,序贯组总成本为266.96元,对照组明显高于序贯组(P<0.01)。结论:加替沙星序贯疗法与单纯静脉滴注相比更安全、更经济。

OBJECTIVE： To evaluate the pharmacoeconomic outcome of sequential therapy of gatifloxacin for acute urinary system infections. METHODS： 76 patients with acute urinary system infections were randomly divided into two groups： 37 cases in comparison group （Group A） were treated with gatifloxacin 200 mg iv gtt bid for 8 d, and 39 in sequential group （Group B） with gatifloxacin 200 mg iv gtt bid for 4 d followed by oral administration of gatifloxacin tablets 200 mg bid for 4 d. The curative efficacy in two groups was observed and cost -effectiveness analysis was performed. RESULTS： The effective rate was 97.3% in control group versus 94.9% in sequential group; the adverse reaction rates were 5.4% and 5.1%, and the bacterial clearance rates were 87.8% and 86.5%, respectively, showing no significant difference between the two groups （P 〉 0.05） . However, the total cost in the control group （502.40 yuan） was significantly higher than in the sequential group （266.96 yuan） （P〈0.01） . CONCLUSION： The sequential therapy of gatifloxacin deserves to be used widely for it is more safe and economical than simple intravenous drip of gatifloxacin.